No­vo-Catal­ent deal like­ly to be one-off — with some caveats, in­sid­ers say

An ac­qui­si­tion sim­i­lar to No­vo Hold­ings’ pro­posed $16.5 bil­lion buy for Catal­ent is un­like­ly to hap­pen again be­cause it bucks the trend of phar­ma com­pa­nies shed­ding man­u­fac­tur­ing as­sets, ac­cord­ing to in­sid­ers in­ter­viewed by End­points News.

But, if such a deal were to be re­peat­ed, it would like­ly stay with­in the realm of GLP-1s and man­u­fac­tur­ers with un­der­used Covid-19 sites as po­ten­tial­ly at­trac­tive tar­gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.